D Orazio & Associates Inc. Has $710,000 Stake in Novo Nordisk A/S (NYSE:NVO)

D Orazio & Associates Inc. lessened its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 4.6% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 8,249 shares of the company’s stock after selling 401 shares during the period. D Orazio & Associates Inc.’s holdings in Novo Nordisk A/S were worth $710,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in the business. Daiwa Securities Group Inc. acquired a new stake in Novo Nordisk A/S during the third quarter worth approximately $28,000. Capital Performance Advisors LLP bought a new stake in shares of Novo Nordisk A/S during the 3rd quarter valued at $42,000. Albion Financial Group UT grew its holdings in shares of Novo Nordisk A/S by 121.4% during the 4th quarter. Albion Financial Group UT now owns 507 shares of the company’s stock worth $44,000 after purchasing an additional 278 shares in the last quarter. Sound Income Strategies LLC increased its position in shares of Novo Nordisk A/S by 82.1% in the fourth quarter. Sound Income Strategies LLC now owns 539 shares of the company’s stock worth $46,000 after purchasing an additional 243 shares during the period. Finally, Hager Investment Management Services LLC bought a new position in Novo Nordisk A/S in the 4th quarter valued at about $46,000. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S Trading Down 0.9 %

Shares of NVO stock opened at $86.39 on Friday. Novo Nordisk A/S has a 1-year low of $78.17 and a 1-year high of $148.15. The company has a current ratio of 0.74, a quick ratio of 0.75 and a debt-to-equity ratio of 0.62. The stock has a market cap of $387.66 billion, a price-to-earnings ratio of 26.26, a PEG ratio of 0.96 and a beta of 0.45. The stock has a 50-day moving average of $91.86 and a 200-day moving average of $111.83.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, beating analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. On average, equities research analysts forecast that Novo Nordisk A/S will post 3.86 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The company also recently announced a semi-annual dividend, which will be paid on Tuesday, April 8th. Investors of record on Monday, March 31st will be issued a $0.7874 dividend. This is a positive change from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. The ex-dividend date is Monday, March 31st. This represents a yield of 1.2%. Novo Nordisk A/S’s payout ratio is presently 21.88%.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the stock. Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. UBS Group upgraded Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. BMO Capital Markets decreased their target price on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research note on Monday, December 23rd. Finally, BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $145.25.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.